MedPath

DERMAVANT SCIENCES, INC.

🇺🇸United States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website

A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck Region

Phase 4
Completed
Conditions
Psoriasis
Interventions
First Posted Date
2023-03-29
Last Posted Date
2024-08-09
Lead Sponsor
Dermavant Sciences, Inc.
Target Recruit Count
31
Registration Number
NCT05789576
Locations
🇺🇸

Dermavant Investigative Sites, Rockville, Maryland, United States

🇺🇸

Dermavant Investigative Site, Arlington, Texas, United States

A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque Psoriasis

Phase 4
Completed
Conditions
Psoriasis
Interventions
First Posted Date
2023-01-11
Last Posted Date
2024-07-08
Lead Sponsor
Dermavant Sciences, Inc.
Target Recruit Count
34
Registration Number
NCT05680740
Locations
🇺🇸

Dermavant Investigative Site, Webster, Texas, United States

Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis

Phase 2
Completed
Conditions
Atopic Dermatitis
Interventions
First Posted Date
2022-01-11
Last Posted Date
2023-07-06
Lead Sponsor
Dermavant Sciences, Inc.
Target Recruit Count
36
Registration Number
NCT05186805
Locations
🇨🇦

Dermavant Investigative Site, Calgary, Alberta, Canada

Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects

Phase 3
Recruiting
Conditions
Plaque Psoriasis
Interventions
First Posted Date
2021-12-29
Last Posted Date
2024-12-10
Lead Sponsor
Dermavant Sciences, Inc.
Target Recruit Count
100
Registration Number
NCT05172726
Locations
🇨🇦

Dermavant Clinical Trials, Oshawa, Ontario, Canada

🇨🇦

Dermavant Clinical Site, Montréal, Quebec, Canada

Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis

Phase 3
Completed
Conditions
Atopic Dermatitis
Interventions
First Posted Date
2021-12-03
Last Posted Date
2024-07-08
Lead Sponsor
Dermavant Sciences, Inc.
Target Recruit Count
728
Registration Number
NCT05142774
Locations
🇺🇸

Dermavant lnvestigative Site, Greenville, South Carolina, United States

🇨🇦

Dermavant Investigative Site, Montréal, Quebec, Canada

Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102)

Phase 3
Completed
Conditions
Atopic Dermatitis
Interventions
Drug: vehicle cream
First Posted Date
2021-09-02
Last Posted Date
2024-07-08
Lead Sponsor
Dermavant Sciences, Inc.
Target Recruit Count
406
Registration Number
NCT05032859
Locations
🇺🇸

Dermanvant Investigative Site, Brooklyn, New York, United States

🇨🇦

Dermavant Investigative Site, Windsor, Ontario, Canada

Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults

Phase 3
Completed
Conditions
Atopic Dermatitis
Interventions
Drug: Vehicle cream
First Posted Date
2021-08-20
Last Posted Date
2024-07-08
Lead Sponsor
Dermavant Sciences, Inc.
Target Recruit Count
407
Registration Number
NCT05014568
Locations
🇨🇦

Dermavant Investigative Site, Montréal, Quebec, Canada

© Copyright 2025. All Rights Reserved by MedPath